Judge Overturns Dismissal of I-75 Corridor Opioid Suit

Sep 11, 2019 | Branstetter Stranch & Jennings

Lawsuit against prescription opioid producers to move forward again

KNOXVILLE, Tenn. — A landmark regional opioid suit brought by six Tennessee district attorney generals against major pharmaceutical manufacturers is back on track.

Judge D. Michael Swiney, Tennessee Court of Appeals at Knoxville, ruled today to reverse last fall’s judgment by Eighth Judicial District Judge John D. McAfee granting multiple motions from pharmaceutical producers to dismiss what is known as the I-75 Corridor opioid lawsuit.

In his ruling, Judge Swiney determined that drug manufacturers can be liable under Tennessee’s Drug Dealer Liability Act (DDLA), and that the manufacturer defendants did not meet their burden in their motion to dismiss the claim. The case has now been remanded to the Trial Court.

The lawsuit was jointly filed on Sept. 29, 2017, in Campbell County Circuit Court in Jacksboro by the district attorneys general of Tennessee’s Sixth, Seventh, Eighth, Ninth and Tenth Judicial Districts, and later amended to also include the Fourth Judicial District.

“This is a substantial victory for the cities and counties represented in this case, and sound affirmation of our complaint,” says Jared Effler, district attorney general for Tennessee’s Eighth Judicial District. “The court clearly recognizes the rights of district attorneys to bring suit on behalf of their constituents, and also agrees that pharmaceutical companies and distributors can be challenged under the DDLA — particularly when these companies knowingly inflict harm on the public, as we believe the defendants have done over a span of many years. We look forward to bringing this case to trial and holding these companies accountable for the damage they have inflicted.”

The complaint lists prescription opioid manufacturer Purdue Pharma, L.P. and its related companies, along with Mallinckrodt LLC, Endo Health Solutions, Inc. and its wholly owned subsidiary, Endo Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc.

“The manufacturer defendants knowingly flooded the affected areas with drugs they knew would later be diverted,” says J. Gerard Stranch, managing partner for Nashville, Tennessee-based law firm Branstetter, Stranch & Jennings, PLLC. “They actively enabled events from the top down for the sake of profit and knowingly participated in Tennessee’s illegal drug market. That is the basis for civil liability under the DDLA, whether the activity happens in a back alley or at a corporation’s headquarters. We look forward to presenting the facts to a jury in the near future.”

The I-75 Corridor suit, which focuses on an area designated as a High Intensity Drug Trafficking Area (HIDTA), demands judgment against the defendants for damages, and seeks restitution for the plaintiffs and an injunction to stop the flood of opioids to the region.

For additional facts, resources and documentation surrounding this issue, visit




Corporate Image

Get In Touch